Navigating the Intersection of Australia's Cell Therapy Regulatory Frameworks
Why This Matters
Sponsors developing cell therapy products for the Australian market must satisfy not one regulatory framework but four overlapping ones — and it's the way these frameworks interact, rather than any single framework in isolation, where most practical difficulty arises. This is particularly true for sponsors entering Australia from the US or EU, where the regulatory architecture is structured differently and where assumptions carried over from FDA or EMA experience don't transfer cleanly.
Public guidance documents describe each framework on its own terms. What they don't do — and what sponsors consistently underestimate — is explain how the three frameworks resolve against one another when a single manufacturing or clinical development decision touches all three at once.
The Four Frameworks
1. PIC/S Annexes 2A and 13. Australia's GMP expectations for advanced therapy products and investigational medicinal products are built on the PIC/S Guide to GMP, with Annex 2A (manufacture of biological medicinal substances and products for human use) and Annex 13 (investigational medicinal products) setting the baseline expectations sponsors typically anticipate from prior US or EU experience.
2. The Australian Code of GMP for Human Blood, Tissues and Cellular Therapy Products. PIC/S Annex 2A itself acknowledges that other national legislation may govern ATMP starting materials — for tissues and cells, legislation covering donation, procurement, testing, processing, preservation, storage and distribution; for blood and blood components, national requirements for donor selection, collection and testing. In Australia, that national legislation is the Australian Code of GMP for Human Blood and Blood Components, Human Tissues and Human Cellular Therapy Products. Where a product's starting material is human-derived — as is the case for autologous and allogeneic cell therapies — the Australian Code applies in addition to Annex 2A, not instead of it.
If you've gone looking for the GMP rulebook for an allogeneic cell therapy, the instinct is to reach for PIC/S Annex 2A, and if you're still investigational, Annex 13 — exactly the frameworks your counterparts in the EU or UK would be working to. That instinct is correct as far as it goes, but incomplete on its own. Annex 2A governs the ATMP manufacturing process itself; the Australian Code governs how the human-derived starting material was donated, procured, tested, processed, and stored before it entered that process. Sponsors who treat Annex 2A as the whole picture — because that's what their global template assumes — can build a manufacturing quality system that's compliant for the ATMP but has a gap at the starting-material stage, where the Australian Code's requirements sit.
A few consequences worth sitting with:
- Your quality system needs two reference frameworks, not one. The Australian Code isn't a lightly localised version of Annex 2A, and it isn't a substitute for it either. It has its own structure, originating from a different regulatory lineage — blood and tissue banking practice rather than pharmaceutical ATMP manufacture — and its expectations around donor eligibility, traceability, and starting material qualification sit alongside, not inside, Annex 2A's requirements for the ATMP manufacturing process. A gap analysis that only checks Annex 2A boxes will miss the starting-material obligations the Code adds.
- It applies regardless of your product's clinical classification. Whether your allogeneic therapy is heading toward biological registration or is still in the investigational trial phase, the human-origin trigger for the Australian Code applies at the level of the starting material — not at the level of where the product sits in development. This is a common point of confusion for sponsors used to jurisdictions where a single GMP framework governs the whole product regardless of development stage.
- Dual sourcing complicates things further. Some allogeneic platforms draw on both human and non-human elements — feeder cells, animal-derived reagents, or hybrid starting materials. Where this occurs, sponsors typically need to satisfy the Australian Code for the human-derived components, Annex 2A for the ATMP manufacturing process, and the PIC/S Annexes generally for anything animal-derived elsewhere in the process. Mapping exactly which framework governs which stage, and building a quality system that satisfies all of them without duplicating effort, is a genuinely non-trivial CMC design question — one worth resolving early, before facility design and SOPs are locked in.
Worth noting: which pathway ultimately governs a given product also depends on its regulatory classification — whether it's regulated as a medicine or via Australia's separate biologicals framework, changes how these obligations stack. That classification question is itself worth resolving early, and is exactly the kind of determination that shapes everything downstream.
3. The Schedule 7 Item 1 Exemption Early-phase sponsors may rely on the Schedule 7 Item 1 manufacturing exemption (Therapeutic Goods Regulations 1990) to conduct clinical trials without a TGA GMP-licensed facility. This exemption has a narrow scope and carries legal uncertainty once a trial moves toward a patient population rather than a strictly controlled early cohort.
4. Australian Regulatory Guidelines for Biologicals (ARGB)
The ARGB is the TGA's guidance set for products regulated as biologicals under Part 3-2A of the Therapeutic Goods Act 1989, covering classification, dossier requirements, applicable standards (TGO 109, TGO 107, TGO 105), access pathways for unapproved product, and post-market obligations.
Most gene-modified cell therapies sit here rather than in the medicines framework. CAR-T is the clearest case: because the cells are manipulated ex vivo to introduce a function not intrinsic to them, the product classifies as a Class 4 biological — the highest-risk tier, carrying a full quality, safety and efficacy dossier, evidence of manufacturing compliance, and a Risk Management Plan.
Which pathway governs a product is not a labelling exercise. The ex vivo / in vivo distinction sends structurally similar therapies down different frameworks: an autologous gene-modified cell product is a biological under section 32, while a vector-delivered in vivo gene therapy is a prescription medicine under section 23. That single determination changes the application form, the evaluation branch, the dossier expectations, the applicable manufacturing principles, and the post-market obligations that stack on top.
It is worth resolving early — at concept stage, via the TGA's Request for advice on biologicals form or a pre-submission meeting — rather than mid-dossier.
Where the Complexity Actually Lives
None of these four frameworks is, by itself, unusually difficult to interpret. The difficulty is combinatorial:
- A sponsor relying on the Schedule 7 Item 1 exemption to avoid early TGA GMP licensing must still determine how the Australian Code applies alongside Annex 2A to their starting material handling, since the exemption doesn't suspend that determination.
- A sponsor running a parallel US IND while pursuing an Australian trial under the exemption may need to reconcile two different manufacturing compliance postures simultaneously — FDA cGMP expectations on one side, and an exemption-dependent, non-GMP-licensed Australian posture on the other — without creating a compliance gap that surfaces only at scale-up or at the transition to a patient-population trial.
- The point at which the Schedule 7 exemption becomes legally uncertain doesn't align neatly with any single milestone in the Annex or Code frameworks, which means sponsors can find themselves needing a TGA GMP licence on a timeline driven by trial design decisions made months earlier — often before the manufacturing strategy was finalised.
The Practical Risk for US/EU Entrants
Sponsors with FDA or EMA experience tend to bring a mental model in which GMP obligations scale predictably with trial phase. Australia's framework doesn't behave this way: obligations are triggered by the interaction of starting-material source, exemption eligibility, and pathway choice, not by phase alone. Sponsors who plan their Australian manufacturing strategy by analogy to their US or EU experience frequently discover — late, and at cost — that the analogy doesn't hold. Sponsors who assume global harmonisation and build to Annex 2A first tend to discover the gap during a TGA GMP licensing review, which is the most expensive place to discover it.
The Advisory Takeaway
None of this is a reason to avoid the Australian market. It's a reason to sequence regulatory strategy work before the manufacturing build, not after — mapping all three frameworks against the sponsor's specific manufacturing plan and trial design from the outset, rather than treating GMP compliance as a single checklist applied uniformly across phases. This is the kind of cross-framework strategic mapping that doesn't appear in any single piece of public guidance, because no single guidance document is written to address the interaction. It is, by nature, advisory work.
If your program is navigating the intersection of these frameworks — or you're not yet sure which one actually governs your starting material — I'd welcome a conversation.
---
Penny Field is Founder and Principal of Keystone Biologics Advisory, a Melbourne-based regulatory consulting practice specialising in cell and gene therapy development, and CMC strategy from Phase 1 through approval.
Sources: PIC/S Guide to GMP for Medicinal Products (Annexes 2A & 13); Australian Code of GMP for Human Blood and Blood Components, Human Tissues and Human Cellular Therapy Products; Therapeutic Goods Regulations 1990, Schedule 7.
This article is general information only and does not constitute regulatory, legal, or professional advice. It should not be relied upon as a substitute for engagement-specific advice tailored to your product and circumstances.